|
2-[4-(Hydroxy-Methoxy-Methyl)-Benzyl]-7-(4-Hydroxymethyl-Benzyl)-1,1-Dioxo-3,6-Bis-Phenoxymethyl-1lambda6-[1,2,7]Thiadiazepane-4,5-Diol
|
DB04042 |
|
|
Carboxymycobactin T
|
DB04043 |
|
|
CP-945598
|
DB05372 |
[CP-945598 is an investigational drug which is a Cannabinoid-1 (CB-1) receptor antagonist being developed for the treatment of obesity.] |
|
N-(2-Morpholin-4-Yl-1-Morpholin-4-Ylmethyl-Ethyl)-3-Nitro-5-(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yloxy)-Benzamide
|
DB04040 |
|
|
Nitrocefin Acyl-Serine
|
DB04041 |
|
|
ACR-16
|
DB05371 |
[ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington’s disease, Parkinson’s disease and schizophrenia respectively. ACR-16 is a dopamine stabilizer. ACR-16 is also being studied in other psychiatric and neurologic diseases.] |
|
N-Carbamoyl-Alanine
|
DB04048 |
|
|
Coelenteramide
|
DB04049 |
|
|
Methyl beta-galactoside
|
DB04046 |
|
|
[Pterin-6-Yl Methanyl]-Phosphonophosphate
|
DB04047 |
|
|
Chlorfenson
|
DB05377 |
[Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.] |
|
Arundic acid
|
DB05343 |
[Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).] |
|
Golimumab
|
DB06674 |
[Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.] |
|
2'-(4-Dimethylaminophenyl)-5-(4-Methyl-1-Piperazinyl)-2,5'-Bi-Benzimidazole
|
DB04011 |
|
|
(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine
|
DB04012 |
|
|
Almorexant
|
DB06673 |
|
|
2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
|
DB04010 |
|
|
ATL-2502
|
DB05340 |
[ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.] |
|
Odanacatib
|
DB06670 |
[Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388]. The drug made it to phase III trials before abandoned due to increased stroke.] |
|
Clorgiline
|
DB04017 |
[An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.] |
